An Asian, Multicenter, Randomized, Double-blind, Placebo-controlled, 14-week Study of Mirogabalin in Participants With Central Neuropathic Pain Followed by a 52-week, Open-label Extension
收藏DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009959/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Investigate the efficacy and safety of mirogabalin in participants with central neuropathic
pain in comparison to placebo
提供机构：
Vivli
创建时间：
2024-04-05
